POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...Genmab to acquire ProfoundBio for USD 1.8 billion in cashAcquisition will give Genmab...March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of...More Posts
Company
Shanghai
Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong
US
2735 Sand Hill Road, Suite 210
Menlo Park, CA 94025
copyright © 2018 Lilly Asia Ventures all rights reserved.
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png